Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral dnaJP1 - Adeona Pharmaceuticals

Drug Profile

Oral dnaJP1 - Adeona Pharmaceuticals

Alternative Names: AT-001; dnaJ peptide; dnaJP1

Latest Information Update: 04 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California, San Diego
  • Developer Adeona Pharmaceuticals
  • Class Antirheumatics; Immunotherapies; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 31 Mar 2011 Discontinued - Phase-II for Rheumatoid arthritis in USA (PO)
  • 30 Nov 2010 Adeona Pharmaceuticals' dnaJP1 is available for licensing as of 30 Nov 2010. http://www.adeonapharma.com/dnajp1.php
  • 30 Sep 2009 Oral dnaJP1 is available for licensing worldwide (http://www.adeonapharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top